drugset
drugset / Trial / NCT01712412

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

NCT01712412 ↗

Phase 2 Terminated 10 enrolled Ironwood Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are to determine the safety and efficacy of IW-9179 administered to patients with functional dyspepsia (FD).

Timeline

Start
2012-10
Primary completion
2014-02
Completion
2014-03

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject RECANACLOTIDE Protein / enzyme biologic — Oral

Indications

dyspepsia